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ABStRACt
Hemostasia is a defense mechanism that protects vascular integrity, avoids blood loss, and maintains blood fluidity throug-
hout the circulatory system. The biochemical processes leading to blood clot formation are complex, and alterations can 
appear at any point within the chain of events. While a range of alterations can affect the coagulation factors, some are 
more common than others in the general population, including congenital (hemophilia A and B, Von Willebrand’s disease) 
and acquired disorders (anticoagulant drugs). Such diseases require special consideration in the context of dental treatment, 
and therefore must be known to dental professionals. Interconsultation with the hematologist will provide orientation on 
the characteristics of the disease and on the best approach to treatment, including the need for replacement therapy, the 
application of local hemostatic measures, the modification of anticoagulant therapy, etc. In any case, the most important 
concern is the prevention of bleeding complications by compiling a detailed clinical history, with adequate planning of 
treatment, and taking special care to avoid soft tissue damage during the dental treatment of such patients. The dental 
surgeon must enhance awareness among patients and their relatives of the importance of correct oral hygiene, which will 
help avoid the need for invasive dental treatments and will reduce the number of visits to the dentist.
Key words: Hemostasia, coagulation factors, hemophilia, Von Willebrand’s disease, anticoagulant drugs, interconsultation, 
bleeding accidents, prevention.
RESUMEN
La hemostasia es un mecanismo de defensa cuya finalidad es conservar la integridad vascular y evitar la pérdida de 
sangre, a la vez que mantiene la fluidez de la sangre en todo el torrente circulatorio. Los procesos bioquímicos que 
conducen a la formación de coágulos son complejos y pueden producirse trastornos  a cualquier nivel. Las alteraciones 
que afectan a los factores de la coagulación son múltiples, pero algunas de ellas se presentan con más frecuencia en la 
población: congénitas (hemofilias A y B, enfermedad de von Willebrand) y adquiridas (fármacos anticoagulantes).Es-
tas patologías requieren consideraciones especiales en el tratamiento dental, por lo que el odontólogo debe conocerlas. 
La interconsulta con el hematólogo del paciente le informará sobre las características de la enfermedad y las pautas 
de tratamiento: necesidad de terapia sustitutiva, empleo de medidas hemostáticas locales,  alteración de la pauta de 
tratamiento anticoagulante, etc. En cualquier caso, la medida más importante a tomar es la prevención de complica-
ciones hemorrágicas mediante la elaboración de una correcta y detallada historia clínica, la planificación adecuada de 
los tratamientos y prestando especial cuidado de no dañar los tejidos blandos orales durante la terapéutica dental. Es 
labor del odontólogo concienciar al paciente y a sus familiares de que una correcta higiene oral evitará la necesidad de 
tratamientos dentales invasivos y reducirá las visitas al odontólogo.
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INtRODUCtION
Hemostasia is a defense mechanism that protects vascular 
integrity, avoids blood loss, and maintains blood fluidity 
throughout the circulatory system (1,2). When a blood vessel 
is damaged, rupture of the endothelial lining exposes the 
blood to proteins within the subendothelial tissue; this in 
turn triggers three different but overlapping mechanisms 
(3):
- Vasoconstriction (vascular phase). Immediately after da-
mage to the vascular wall, reflex vasoconstriction occurs, 
reducing blood flow from the damaged vessel (1,4).
- Platelet plug formation (platelet phase). The blood plate-
lets adhere to the exposed collagen fibers in the damaged 
vascular wall, and also to each other - thus forming a pla-
telet plug (2).
- Fibrin production to stabilize and strengthen the platelet 
plug (plasmatic phase). Plasmatic coagulation involves the 
transformation of fibrinogen (soluble) into fibrin (insoluble) 
via the mediation of thrombin, a proteolytic enzyme genera-
ted as a result of the activation of prothrombin. The trans-
formation of prothrombin into thrombin in turn takes place 
via two pathways, intrinsic and extrinsic - though in fact 
both pathways interact continuously. The intrinsic pathway 
is triggered by the activation of coagulation factor XII as a 
result of contact between the latter and the subendothelial 
tissues in the damaged zone. The extrinsic pathway in turn 
is triggered when the blood comes into contact with tissue 
thromboplastin released by the damaged tissues, resulting 
in the activation of coagulation factor VII. From this point 
onwards, a cascade of metabolic reactions occurs, involving 
the different coagulation factors - with the formation of 
thrombin as end result (Table 1).
The blood clot is finally dissolved during the fibrinolytic 
phase. When the damaged vessel wall is repaired, activated 
factor XII facilitates the conversion of an inactive molecule 
present in plasma into an active form called kallikrein. The 
latter in turn catalyzes the conversion of inactive plasmino-
gen into the active molecule plasmin - an enzyme that digests 
fibrin to yield degradation products, and thus facilitates clot 
dissolution (3).
LABORAtORY tEStS
A number of  tests are available for evaluating patients 
with coagulation disorders in order to diagnose the precise 
deficiency involved:
- Bleeding time: This test assesses the vascular and platelet 
phases of blood clotting. Although it is a functional test of 
limited sensitivity, it remains a good screening option (5).
- Activated partial thromboplastin time (aPTT): This test 
evaluates the intrinsic and common pathways of  blood 
coagulation (2,5).
- Prothrombin time (PT): This parameter evaluates the 
extrinsic and common pathways (2,5), though it has been 
found to be inexact and variable, and the values obtained in 
different laboratories are not comparable due to the different 
thromboplastin sources used. Indeed, such differences have 
led to bleeding problems secondary to excessive anticoagu-
lation based on erroneously low PT values (5). In order to 
standardize PT, the World Health Organization (WHO) 
in 1983 introduced the International Normalized Ratio 
(INR)(6), which is the ratio between the PT of the patient 
in seconds and a control PT standardized by means of the 
so-called International Sensitivity Index (ISI), which indi-
cates the sensitivity of the thromboplastin used as reagent. 
In this context, human brain thromboplastin is designated 
the reference standard of 1.0. For a PT value within the 
normal range, INR = 1 (1,5-7).
- Specific factor tests.
Table 2 reports the normal ranges for these parameters, toge-
ther with the disorders in which the values can be altered.
CLASSIFICAtION OF COAGULAtION FACtOR 
DISORDERS 
The processes that lead to the formation of blood clots are com-
plex, and alterations can take place at any level. The present review 
focuses on those alterations that affect the coagulation factors, and 
which can be classified as either congenital or acquired (Table 3). 
Due to the broad range of described alterations, we will 
Palabras clave: Hemostasia, factores de coagulación, hemofilia, enfermedad de von Willebrand, fármacos anticoagulantes, 
interconsulta, accidentes hemorrágicos, prevención.
Activation through                  Tissue 
contact triggers the                                                 thromboplastin starts  









Factor X + Ca + platelet F3 
Prothrombin                   Thrombin 
    Fibrinogen  Fibrin         
table I. Plasmatic coagulation cascade.
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a) Congenital
Hemophilia A (deficiency of portion VIIIc of factor VIII 
complex)
Hemophilia B or Christmas disease (factor IX deficiency)
Von Willebrand disease (alteration of factor VIII)
Fibrinogen alterations






Combined deficiency of vitamin K-dependent factors (VII, IX, 
X)
Combined deficiency of factors V and VIII
Combined deficiency of factors VII and VIII





i. Malabsorption or liver diseases
ii. Prolonged antibiotic treatment
iii. Insufficient ingestion of the vitamin
Acquired anticoagulants
Disseminated intravascular coagulation (DIC)
Primary fibrinogenolysis
Anticoagulant drugs
Test Normalvalue Increased in Normal in Reduced in 
Bleeding time 1-6 min Von Willebrand disease Hemophilia A and B
aPTT 25-35 s 
Hemophilia A and B, 
DIC, liver disease, 
vitamin K deficiency, 
coumarins
PT/INR 11-15 s 
DIC, liver disease, 
vitamin K deficiency, 
coumarins
Hemophilia A and 
B




Hemophilia A, von 
Willebrand disease, 
DIC
Factor IX 60-100%   Hemophilia B 
Factor VII 60-100%   Liver disease, vitamin K deficiency, DIC 
Factor V 60-100%  Vitamin K deficiency Liver disease, DIC 
table 2. Secondary hemostasia disorders.
table 3. Laboratory tests.
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limit in-depth examination to the most frequent disorders: 
hemophilia A and B and Von Willebrand’s disease among 
the congenital presentations, and anticoagulant drug admi-
nistration in representation of the acquired disorders.
CONGENItAL DISORDERS
1.- HEMOPHILIA A
Definition and epidemiology. Hemophilia A is a hereditary 
bleeding disorder characterized by a deficiency in the activi-
ty of coagulation factor VIII (FVIII) in plasma, though with 
normal von Willebrand factor (FvW). The frequency in the 
general population is 1/5000 live born males (4,8,9). 
Etiology and Pathogenesis. The disease shows X chromoso-
me-linked hereditary transmission. As a result, women are 
able to carry the disease but do not suffer from it. The only 
exception is the rare case of a woman with a hemophiliac 
father and carrier mother (8,10). 
Depending on the FVIII levels, three disease grades have 
been established: severe (< 1% of the normal levels), mo-
derate (1-5% of the normal levels) and mild (5-50% of the 
normal levels)(4,5,8,11). 
Clinical manifestations. The principal sign is bleeding; all 
other manifestations are a consequence of the latter (10). 
Severe hemophilia is characterized by spontaneous bleeding 
of the joints and sometimes also of the soft tissues; any minor 
traumatism can lead to potentially life-threatening hemorr-
hage (5). The accumulation of bleeding episodes in the joints 
is associated with a high risk of developing joint disease. 
Bleeding within muscle tissue in turn can produce hematomas 
that cause pain, inflammation and dysfunction (8). 
Diagnosis. The diagnosis is usually established from the 
clinical history. In this sense, hemophilia can be suspected 
from a family history of bleeding only in males, or from an 
exaggerated bleeding response to minor traumatisms and 
dental manipulations (1). The laboratory diagnosis is based 
on a very prolonged aPTT, while PT and bleeding time prove 
normal. The definitive diagnosis is established by quantita-
tion of the procoagulant activity of FVIII, which is found 
to be reduced. A differential diagnosis must be established 
with Von Willebrand’s disease (10,11).
DNA analysis has made it possible to detect carriers and to 
establish a prenatal diagnosis in most cases (12). At present, 
preimplantation genetic diagnosis is possible, thus offering 
parents at risk of transmitting the disease the possibility of 
knowing whether the embryo is affected or not (13).
Treatment. The management options are practically limited 
to prophylaxis and the control of bleeding - where replace-
ment therapy plays a preponderant role. Pharmacological 
antihemorrhagic treatment comprises antifibrinolytic agents 
and desmopressin (DDAVP), which are used when the blee-
ding manifestations are mild (10):
- Replacement therapy. Such treatment is based on the ad-
ministration of antihemophilic factor concentrates. Human 
blood plasma products can be used to this effect, or alter-
natively plasma products obtained through recombinant 
technology (8,10). The half-life of FVIII is about 12 hours, 
which in turn determines the dosing interval (10).
The appearance of inhibitors that inactivate the function of 
the replaced factor is one of the most serious complications 
in the treatment of hemophilia. Thirty percent of all patients 
with severe hemophilia develop this problem (8).
- Desmopressin (DDAVP). This is a synthetic vasopressin 
analog that stimulates FVIII and FvW release from the 
endothelial cells and also increases platelet adhesion. Pa-
tients with detectable FVIII levels show a more predictable 
response to DDAVP, while those with undetectable levels 
of the factor fail to respond (14). Administration is usually 
via the intravenous route, though subcutaneous dosing or 
the inhalatory route (involving lesser response) also can be 
used. The administered dose is 0.3-0.4 μg/kg body weight 
as an intravenous infusion during 30 minutes, or as a sub-
cutaneous injection. When the inhalatory route is chosen, 
the recommended dose is 300 μg in adults and 150 μg in 
children (14,15). The advantage is avoidance of the use of 
plasma concentrates (10,16).
- Antifibrinolytic agents. The two most widely used drugs 
are ε-aminocaproic acid (EACA, Caproamin®) and tra-
nexamic acid (AMCHA, Amchafibrin®). These drugs bind 
to the plasminogen binding site, resulting in the inhibition 
of fibrinolysis (14). The oral, intravenous or topical routes 
can be used, with the following doses: EACA 300 mg/kg/day 
in fractions every 4-6 hours; AMCHA 30 mg/kg/day in 2-3 
daily doses (10,15).
- Gene therapy. The latest advances in gene therapy applied 
to hemophilia aim to correct the molecular defect in the 
mutant gene. At present, research is being done to add 
normal genes that encode for FVIII (or FIX in hemophilia 
B), based on recombinant technology (11,17).
Prognosis. With the currently available management options, 
the perspectives for patients with severe hemophilia have 
changed considerably. These individuals are now able to 
lead a normal life with few restrictions. On the other hand, 
gene therapy offers the possibility of true healing of the 
disease in animals - though application to humans is not 
yet possible (11).
Dental considerations. At oral level, the most frequent 
manifestations of  hemophilia are prolonged, gingival 
bleeding episodes (either spontaneous or in response to 
trauma). Hemarthrosis of the temporomandibular joint is 
infrequent (1).
Dental management must center on prevention (measures 
of hygiene, fluor, sealing of cracks, dietary counseling and 
periodic controls) in order to reduce the need for dental 
treatment (18). However, if  prevention is not possible and 
treatment is needed, the dental surgeon should contact the 
hematologist to know the specific characteristics of  the 
disease in each individual patient, as well as the required 
factor replacement regimen based on the programmed 
dental treatment (1). In patients with mild to moderate 
hemophilia, noninvasive dental treatments can be carried 
out under antifibrinolytic coverage, while oral cleaning 
procedures and certain forms of  minor surgery can be 
performed with DDAVP. In severe hemophilia, factor repla-
cement is required (19), with the consideration of hospital 
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admission. This decision is to be taken in coordination with 
the hematologist (5). The administration of local anesthe-
tics is one of the main sources of concern, due to the risk 
of hematomas, airways obstruction and death. Anesthetic 
block or intramuscular injections are never carried out in 
the presence of FVIII levels of less than 50% the normal 
reference value, and in all cases they must be preceded by 
replacement therapy. Infiltrating pericemental and intrabony 
injections are to be preferred (5,12,18).
2.- HEMOPHILIA B
Definition and Epidemiology. Hemophilia B or Christmas 
disease is a congenital coagulation disorder caused by a 
quantitative or qualitative anomaly of coagulation factor 
IX (FIX)(1). The disease is five times less common than 
hemophilia A (8).
Etiology and pathogenesis. The gene encoding for FIX 
is located in chromosome X, i.e., the disease is sex-linked 
(1,12). In the same way as in hemophilia A, three grades 
of hemophilia B are observed: severe, moderate and mild 
(4,5,8,11).
Clinical manifestations. The disease is clinically indistin-
guishable from hemophilia A (8).
Diagnosis. The laboratory diagnosis is based on a very 
prolonged aPTT, while both PT and bleeding time are nor-
mal. The definitive diagnosis is established by quantitation 
of the procoagulant activity of FIX, which is found to be 
reduced (10,11).
Treatment. The principles of  treatment are basically the 
same as in hemophilia A, and consist of FIX replacement 
therapy. The half-life of this factor is 24 hours, i.e., the do-
sing interval is longer than in hemophilia A, though the re-
quired dose is 25-50% greater than in the latter presentation 
of hemophilia (10). DDAVP is not useful in these patients 
(12). The generation of factor inhibitors is observed in less 
than 5% of cases (8).
Dental considerations. The guidelines for dental treatment 
are practically the same as in hemophilia A. 
3.- VON WILLEBRAND’S DISEASE
Definition and Epidemiology. Von Willebrand’s disease (vW 
disease) is considered to be the most common hereditary 
hemorrhagic disorder in humans (8,20), and is characte-
rized by a prolonged bleeding time with low FVIII titers 
(4,12). It affects 1-2% of the general population (8,10,15). 
However, it is very likely that the application of stricter 
epidemiological criteria to differentiate between reductions 
in Von Willebrand factor (FvW) associated with mild or 
moderate bleeding risk and true Von Willebrand’s disease 
would reduce the prevalence (21).
Etiology and pathogenesis. Von Willebrand’s disease is 
characterized by FvW deficit or dysfunction. The main 
functions of this factor are the mediation of platelet adhe-
sion and stabilization of FVIII in the bloodstream (4,10,15). 
As a result, FvW deficiency leads to a combined defect in 
platelet plug formation and fibrin formation (15).
Clinical manifestations. Mucosal membrane bleeding is 
characteristically observed (gingival hemorrhage, epistaxis, 
metrorrhagia), while hemarthrosis and musculoskeletal blee-
ding are only seen in the more severe forms of the disease (1). 
Women commonly present menorrhagia and, in the more 
severe presentations, postpartum bleeding (12). 
Diagnosis. The usual coagulation tests are not sufficient 
for establishing the diagnosis of Von Willebrand’s disease. 
A number of specific tests therefore have been developed. 
In addition to bleeding time, other assays are performed: 
platelet agglutination induced by ristocetin, FvW titration, 
determination of FvW binding to collagen, determination 
of  the antigenic activity of  FvW, and evaluation of  the 
multimeric structure of FvW (10).
Treatment. Management is based on DDAVP (desmo-
pressin), which induces autologous secretion of FvW and 
FVIII from the endothelial cells, and plasma concentrates 
- which allogenically supplement the deficiency of these 
factors (15):
- DDAVP. Intravenous infusion is recommended for the 
treatment of acute bleeding, though the drug can also be 
administered via the subcutaneous or nasal route - which 
are preferred for prophylactic purposes (8,15). Dose testing 
is required to assess the response to treatment of each indi-
vidual patient (10,15).
- Replacement therapy. This is indicated in patients that fail 
to respond to DDAVP or when the latter is contraindicated. 
Replacement therapy is also provided in cases of bleeding 
that prove life-threatening for the patient (8). 10-15% of all 
patients with severe forms of the disease develop autoan-
tibodies against FvW antigen, thus creating complications 
for treatment (10,15).
On a complementary basis, use is also made of antifibri-
nolytic drugs (EACA and AMCHA) via the intravenous, 
oral or topical routes (8,10,15). In women, estrogens have 
been shown to be effective for the treatment of moderate 
menorrhagia (10).
Dental considerations. Prolonged bleeding is commonly 
seen after tooth extractions, as well as excessive bleeding 
associated with dental cleaning procedures (1).
Dental treatment must be individualized according to the 
severity of the condition, in coordination with the hema-
tologist. In patients that respond to DDAVP, the latter is 
administered, while in refractory cases replacement therapy 
is used to reduce postoperative bleeding. The intranasal 
formulation is particularly useful for prevention in dental 
procedures, and has the advantage of allowing ambulatory 
administration. In addition to the above measures, antifi-
brinolytic agents can be administered (EACA, AMCHA), 
via the oral, intravenous or topical routes (1,8,9).
4.- OTHER COAGULATION FACTOR DEFICIEN-
CIES
Congenital deficiencies of coagulation factors other than 
factors VIII (hemophilia A and vW disease) and IX (hemo-
philia B) are rare bleeding disorders (22). Their diagnosis 
and treatment pose important difficulties, due to the low 
frequency of these diseases in the general population (23).
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ACQUIRED DISORDERS
1.- LIVER DISEASE. The liver synthesizes most of the coa-
gulation factors, and is the source of the carboxylase needed 
for the γ-carboxylation of the vitamin K-dependent factors. 
As a result, hepatocellular disease reduces the production 
of all the essential coagulation factors with the exception 
of FVIII and FvW, which are fundamentally produced by 
the endothelial cells (22). 
2.- VITAMIN K DEFICIENCY. Prothrombin and factors 
VII, IX and X are produced in the liver cells, in processes re-
quiring the presence of vitamin K (10). The latter intervenes 
in the γ-carboxylation of these coagulation factors which in 
the absence of carboxylic acid addition are unable to bind 
to calcium, and are therefore functionally inert. 
The most common causes of vitamin K deficiency (exclu-
ding the administration of anticoagulant drugs) are: malab-
sorption and liver diseases, prolonged antibiotic use (which 
eliminates the intestinal flora - a natural source of vitamin 
K2), and insufficient ingestion of the vitamin (12). 
3.- ACQUIRED ANTICOAGULANTS. Acquired anti-
coagulants are type IgG autoantibodies targeted to one or 
more coagulation factors (10,12,24).
4.- DISSEMINATED INTRAVASCULAR COAGULA-
TION (DIC). Disseminated intravascular coagulation is an 
acquired consumption coagulation disorder resulting from 
prolonged activation of the coagulation system. DIC is in-
variably the result of some underlying pathology, and must 
be evaluated in the context of the latter (12). Despite the 
disseminated production of fibrin, the main clinical problem 
of DIC is bleeding as a result of depletion (consumption) 
of the coagulation factors (10).
5.- PRIMARY FIBRINOGENOLYSIS. This disorder ma-
nifests when active plasmin is generated in the bloodstream 
while the coagulation cascade is inactive. Primary fibrinoge-
nolysis can occur in patients with liver disease, lung cancer, 
prostate cancer and heat stroke. Severe bleeding occurs as a 
result of fibrinogen depletion (degraded by plasmin) and the 
formation of fibrin degradation products from fibrinogen, 
which have anticoagulant properties (5).
6.- ANTICOAGULANT DRUGS. Many bleeding ten-
dencies are due to the use of  anticoagulants, which are 
commonly prescribed for underlying cardiological diseases 
such as ischemic heart disease, heart valve problems and the 
implantation of valve prostheses, deep venous thrombosis, 
pulmonary embolism, and cerebrovascular accidents such 
as stroke (1,9,25).
Anticoagulation is provided with unfractionated or standard 
heparin, low molecular weight heparin (LMWH) and oral 
anticoagulants (coumarins)(2,25).
Standard heparin (SH). Standard heparin fundamen-
tally acts as a catalyzer of  plasmatic antithrombin III 
(ATIII)(1,26,27). The latter regulates coagulation, inhibiting 
certain factors of the coagulation cascade, and heparin binds 
to it to reinforce such inactivation (1,26).
SH is used at high doses for the treatment of thromboem-
bolism, and at low doses to prevent the latter. It is generally 
used as an intravenous infusion in hospitalized patients, and 
requires aPTT monitorization. The only patients subjected 
to high dose SH treatment on an ambulatory basis are 
those on hemodialysis, though the effects last only a few 
hours after dialysis, since the half-life of SH is 1-2 hours 
(Figure 1).
Low molecular weight heparin (LMWH). This form of 
heparin exerts the same action as SH, and is used in place 
of the latter in patients programmed for major surgery, for 
the prevention of deep venous thrombosis - administration 
being via the abdominal subcutaneous route. LMWH is 
also used in the treatment of outpatients (25,26). It offers a 
number of advantages over SH. In effect, its longer half-life 
of 2-4 hours (26) allows for more predictable dosing, with a 
lesser need for monitorization, and a reduction in the inci-
dence of heparin-induced thrombocytopenia (9). Moreover, 
the risk of postoperative bleeding is lower, since LMWH 
exerts a lesser effect upon the platelets (25), and its efficacy 
in preventing thromboembolism is greater (26).
Coumarin drugs. These substances comprise warfarin (Al-
documar®) and acenocoumarol (Dicumarol®, Sintrom®), 
which exert an anticoagulative effect as a result of vitamin 
K antagonism and the inhibition of vitamin K-dependent 
coagulation factor synthesis (factors VII, IX, X and pro-
thrombin)(1). They are used at low doses for the treatment 
or prevention of venous thrombosis, and at higher doses in 
patients with heart valve prostheses, or as prevention against 
recurrent myocardial infarction.
Patients treated with oral anticoagulants require periodic 
controls (2). Monitorization is based on PT, since the latter 
is sensitive for three of the vitamin K-dependent coagulation 
factors: VII, X and prothrombin. As has been mentioned 
above, PT is imprecise, and use of  the INR is presently 
recommended (26). The recommended anticoagulation 
levels are equivalent to an INR value of between 2 and 3 
for all indications, with the exception of cardiac valve pros-
theses - where the INR should be kept between 2.5 and 3.5 
(1,2,28)(Figures 2a and 2b). 
Fig. 1. Sublingual hematoma induced by heparin in a patient subjected 
to kidney dialysis in the preceding hours.
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Dental considerations. Most patients treated with SH are 
hospitalized, and once discharged, treatment is continued 
with coumarins. If a dental emergency arises during hospital 
admission, and conservative management is not possible, the 
supervising physician should be consulted (26), to decide 
whether SH can be suspended in order to carry out the 
dental procedure once its effect has disappeared. If  emer-
gency intervention proves necessary, the effect of SH can 
be countered by administering its antagonist, protamine 
sulfate, at an intravenous dose of 1 mg/100 IU of heparin 
(25-27). In dialyzed patients, and since SH has a half-life 
of 1-2 hours, it suffices to carry out any necessary invasive 
dental treatment on the day after dialysis (26). Outpatients 
administered LMWH can undergo invasive dental care 
without changes in medication, and postoperative bleeding 
can be controlled by the adoption of local measures. If  
heavier bleeding is anticipated, the anticoagulant treatment 
can be suspended for a day, with dental treatment taking 
place the day after (26).
There is controversy in the literature regarding the mana-
gement of patients treated with coumarins (9). The great 
majority of authors consider that there is no need to modify 
anticoagulant therapy provided the INR is 4 or lower, since 
possible bleeding can be controlled with local measures, whi-
le the interruption of such medication does not necessarily 
reduce bleeding and moreover entails the risk of serious 
thromboembolic complications (7,25,26,29). In the case 
of important bleeding, vitamin K can be administered to 
revert the effect of medication, though prior consultation 
with the supervising physician is required in all cases (7). 
Lastly, consideration is required of the possible interactions 
of these drugs with other medications which the patient may 
be using, since the anticoagulant effect could be increased 
or reduced as a result (25,26).
CONSIDERAtIONS FOR DENtAL tREAt-
MENt
The most important objective is the prevention of compli-
cations. The following principles apply in this sense:
1. Identification of the patient based on a thorough clinical 
history: disease antecedents, exploration and laboratory 
testing for selective identification (1).
2. Counseling of  patients and their relatives to increase 
awareness of the importance of good oral hygiene in order 
to avoid the need for invasive dental care and reduce the 
number of visits to the dentist (1,19).
3. Consultation with the specialist to determine the type 
of congenital disorder involved, the need or not for repla-
cement therapy and the possible existence of inhibitors, or 
to obtain information on the degree of anticoagulation of 
patients subjected to anticoagulation therapy, and the need 
or not for dose reduction to ensure sufficient hemostasia 
(5,25).
4. Replacement therapy in necessary cases. Replacement 
may comprise coagulation factors (hemophilia A and B, 
and vW disease) or vitamin K (lack of ingestion or poor 
absorption and liver disease)(5,12).
5. Avoidance of brusque maneuvers during dental treat-
ment, in order to prevent oral mucosal damage that may 
give rise to postoperative bleeding problems (1,12,19).
6. Evaluation of the advisability of hospital admission when 
complex surgery is required. In the case of  hemophilia, 
the ideal approach would be to provide dental care in the 
specialized hemophilia center by dental surgeons integrated 
within the team supervising the patient (9).
7. Aspirin and its derivatives are to be avoided as pain treat-
ment. In this sense, paracetamol is a safe alternative (1,18). 
In the case of the coumarins, the possibility of multiple 
interactions with other drugs must be taken into account 
- resulting in either enhancement of the anticoagulant effect 
(with the resulting risk of excessive bleeding), or a reduc-
tion of coumarin effects (with the risk of thromboembolic 
events). Some of these drugs are often prescribed in dental 
practice, including antibiotics (amoxicillin and amoxicillin 
plus clavulanate, ampicillin, azithromycin, erythromycin, 
rifampicin, penicillin G, cephalosporins, sulfonamides, 
metronidazole, chloramphenicol), antifungals (azoles and 
griseofulvin), analgesics (aspirin and other nonsteroidal 
antiinflammatory drugs; paracetamol in excess can enhance 
warfarin action), and psychoactive drugs (some antihista-
mines, diazepam)(25,26).
Fig. 2. (a) Hematoma of the tonsillar region after extraction 
of 2.7 in a patient with Marfan syndrome treated with aceno-
coumarol. 
(b) Plugging with Surgicel® and silk suturing in the same pa-
tient.
E387
Med Oral Patol Oral Cir Bucal 2007;12:E380-7.                                                                                                                                                                                                                 Coagulation factor alterations                                                         Med Oral Patol Oral Cir Bucal 2007;12:E380-7.                                                                                                                                                                                                                Coagulation factor alterations 
8. Reabsorbable sutures are recommended, in order to avoid 
the risk of bleeding associated with suture removal (1,18).
9. Hemophiliacs treated with human plasma derivatives may 
be carriers of hepatitis B or C viruses, HIV, parvovirus or 
transmissible spongiform encephalopathy (1,8,11).
10. Local hemostatic measures are recommendable: mecha-
nical (sutures, compression, splints for protecting the clot), 
chemical agents (thrombin) or reabsorbable hemostatic 
products (oxidized-regenerated cellulose, microfibrilar co-
llagen, fibrin sponges or gelatin plugs) (7).
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